{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:14:01Z","timestamp":1788984841306,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01850-7","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:55:09Z","timestamp":1783058109000},"page":"4387-4402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3446-6648","authenticated-orcid":false,"given":"Francesco","family":"D\u2019Oria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3780-5318","authenticated-orcid":false,"given":"Sara","family":"Di Giulio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-4866","authenticated-orcid":false,"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4009-0544","authenticated-orcid":false,"given":"Costanza","family":"Falcidia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0527-706X","authenticated-orcid":false,"given":"Giulio","family":"Foggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-8710","authenticated-orcid":false,"given":"Carlo Alberto","family":"Vignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5171-9854","authenticated-orcid":false,"given":"Paola","family":"Facheris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1438-9553","authenticated-orcid":false,"given":"Ruggero","family":"Cascio Ingurgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-8581","authenticated-orcid":false,"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"1850_CR1","doi-asserted-by":"publisher","first-page":"e70076","DOI":"10.1111\/jocd.70076","volume":"24","author":"J Zhou","year":"2025","unstructured":"Zhou J, Liang L, Zhang H, Liu M, Zhu Z, Leng L, et al. Global burden of alopecia areata and associated diseases: a trend analysis from 1990 to 2021. J Cosmet Dermatol. 2025;24:e70076. https:\/\/doi.org\/10.1111\/jocd.70076.","journal-title":"J Cosmet Dermatol"},{"key":"1850_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85:379\u201387. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.050.","journal-title":"J Am Acad Dermatol"},{"key":"1850_CR3","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","volume":"366","author":"A Gilhar","year":"2012","unstructured":"Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366:1515\u201325. https:\/\/doi.org\/10.1056\/NEJMra1103442.","journal-title":"N Engl J Med"},{"key":"1850_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. https:\/\/doi.org\/10.1038\/nrdp.2017.11.","journal-title":"Nat Rev Dis Primers"},{"key":"1850_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, Hua T, Rastogi S, Ibler E, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82:675\u201382. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.032.","journal-title":"J Am Acad Dermatol"},{"key":"1850_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s44368-025-00013-8","volume":"2","author":"E Akbaba","year":"2025","unstructured":"Akbaba E, Aydemir E, Ayaz F. Alopecia areata: a comprehensive review of clinical, immunologic, and genetic perspectives. Discov Immun. 2025;2:8. https:\/\/doi.org\/10.1007\/s44368-025-00013-8.","journal-title":"Discov Immun"},{"key":"1850_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-025-00664-9","volume":"11","author":"B Ungar","year":"2025","unstructured":"Ungar B, Renert-Yuval Y, Dlova NC, Jabbari A, King B, Mesinkovska NA, et al. Alopecia areata. Nat Rev Dis Primers. 2025;11:77. https:\/\/doi.org\/10.1038\/s41572-025-00664-9.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1850_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70182","volume":"2025","author":"T Ma","year":"2020","unstructured":"Ma T, Zhang T, Miao F, Liu J, Zhu Q, Chen Z, et al. Alopecia areata: pathogenesis, diagnosis, and therapies. MedComm. 2020;2025(6):e70182. https:\/\/doi.org\/10.1002\/mco2.70182.","journal-title":"MedComm"},{"key":"1850_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043\u20139. https:\/\/doi.org\/10.1038\/nm.3645.","journal-title":"Nat Med"},{"key":"1850_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-020-01293-0","volume":"80","author":"A Pourang","year":"2020","unstructured":"Pourang A, Mesinkovska NA. New and emerging therapies for alopecia areata. Drugs. 2020;80:635\u201346. https:\/\/doi.org\/10.1007\/s40265-020-01293-0.","journal-title":"Drugs"},{"key":"1850_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.01.055","author":"A Martin","year":"2026","unstructured":"Martin A, Chen L-C, Kreytak C, Farah R, Hordinsky M, Lo Sicco KI, et al. Switching between Janus kinase inhibitors for treatment of alopecia areata: a multicenter retrospective review. J Am Acad Dermatol. 2026. https:\/\/doi.org\/10.1016\/j.jaad.2026.01.055.","journal-title":"J Am Acad Dermatol"},{"key":"1850_CR12","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/1744666X.2025.2575365","volume":"21","author":"H-J Lai","year":"2025","unstructured":"Lai H-J, Ye Z-M, Chen S-Q, McElwee KJ, Guo H-W. Immune therapies for alopecia areata: evidence and new perspectives. Expert Rev Clin Immunol. 2025;21:1421\u201346. https:\/\/doi.org\/10.1080\/1744666X.2025.2575365.","journal-title":"Expert Rev Clin Immunol"},{"key":"1850_CR13","volume-title":"Olumiant: EPAR\u2014product information","author":"European Medicines Agency","year":"2017","unstructured":"European Medicines Agency. Olumiant: EPAR\u2014product information. Amsterdam: European Medicines Agency; 2017."},{"key":"1850_CR14","volume-title":"Litfulo: EPAR\u2014product information","author":"European Medicines Agency","year":"2023","unstructured":"European Medicines Agency. Litfulo: EPAR\u2014product information. Amsterdam: European Medicines Agency; 2023."},{"key":"1850_CR15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jaad.2025.11.070","volume":"94","author":"A Tsianakas","year":"2026","unstructured":"Tsianakas A, Passeron T, Magnolo N, Blume-Peytavi U, Kelly V, Day I, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol. 2026;94:1134\u201343. https:\/\/doi.org\/10.1016\/j.jaad.2025.11.070.","journal-title":"J Am Acad Dermatol"},{"key":"1850_CR16","first-page":"1","volume":"31","author":"A Robbins","year":"2026","unstructured":"Robbins A, Phillips M. Deuruxolitinib for alopecia areata. Skin Ther Lett. 2026;31:1.","journal-title":"Skin Ther Lett"},{"key":"1850_CR17","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/jdv.20372","volume":"39","author":"D Aceituno","year":"2025","unstructured":"Aceituno D, Fawsitt CG, Power GM, Law E, Vaghela S, Thom H. Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. An Bras Dermatol. 2025;39:1134\u201342. https:\/\/doi.org\/10.1111\/jdv.20372.","journal-title":"An Bras Dermatol"},{"key":"1850_CR18","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"key":"1850_CR19","doi-asserted-by":"publisher","first-page":"AB251","DOI":"10.1016\/j.jaad.2024.07.996","volume":"91","author":"M Senna","year":"2024","unstructured":"Senna M, Mostaghimi A, Ohyama M, Sinclair R, Chiasserini C, Dutronc Y, et al. 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2. J Am Acad Dermatol. 2024;91:AB251. https:\/\/doi.org\/10.1016\/j.jaad.2024.07.996.","journal-title":"J Am Acad Dermatol"},{"key":"1850_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.064","author":"M Piliang","year":"2025","unstructured":"Piliang M, Lynde C, King B, Mirmirani P, Sinclair R, Senna M, et al. Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: post hoc analysis of the ALLEGRO phase 2b\/3 trial. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.064.","journal-title":"J Am Acad Dermatol"},{"key":"1850_CR21","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401:1518\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(23)00222-2.","journal-title":"Lancet"},{"key":"1850_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-01029-y","author":"M Senna","year":"2026","unstructured":"Senna M, Soung J, Figueras I, King B, Kinoshita-Ise M, Hanna S, et al. Long-term efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: 3-year results from the ALLEGRO phase 2b\/3 and ALLEGRO-LT phase 3 clinical studies. Am J Clin Dermatol. 2026. https:\/\/doi.org\/10.1007\/s40257-026-01029-y.","journal-title":"Am J Clin Dermatol"},{"key":"1850_CR23","doi-asserted-by":"publisher","first-page":"2268764","DOI":"10.1080\/09546634.2023.2268764","volume":"34","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Vignoli CA, Ferrucci SM, Mercuri SR, Malagoli P, et al. Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience. J Dermatol Treat. 2023;34:2268764. https:\/\/doi.org\/10.1080\/09546634.2023.2268764.","journal-title":"J Dermatol Treat"},{"key":"1850_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2444494","volume":"36","author":"CA Vignoli","year":"2025","unstructured":"Vignoli CA, Gargiulo L, Ibba L, Balato A, Barbareschi M, Barruscotti S, et al. Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study. J Dermatol Treat. 2025;36:2444494. https:\/\/doi.org\/10.1080\/09546634.2024.2444494.","journal-title":"J Dermatol Treat"},{"key":"1850_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/jdv.70067","volume":"40","author":"BM Piraccini","year":"2026","unstructured":"Piraccini BM, Cedirian S, Pampaloni F, Rapparini L, Quadrelli F, Bruni F, et al. Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results. J Eur Acad Dermatol Venereol. 2026;40:224\u201331. https:\/\/doi.org\/10.1111\/jdv.70067.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1850_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-01022-5","author":"M Starace","year":"2026","unstructured":"Starace M, Rapparini L, Pampaloni F, Cedirian S, Quadrelli F, Bruni F, et al. Ritlecitinib for severe alopecia areata: a 24-week, multicentre, real-world study. Am J Clin Dermatol. 2026. https:\/\/doi.org\/10.1007\/s40257-026-01022-5.","journal-title":"Am J Clin Dermatol"},{"key":"1850_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.70241","author":"R Hayashi","year":"2026","unstructured":"Hayashi R, Takamura S, Fukuda T. Real-world outcomes of baricitinib and ritlecitinib in refractory alopecia areata: response predictors and relapse after discontinuation or dose reduction. J Dermatol. 2026. https:\/\/doi.org\/10.1111\/1346-8138.70241.","journal-title":"J Dermatol"},{"key":"1850_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/ced\/llaf509","volume":"51","author":"L Foggia","year":"2026","unstructured":"Foggia L, Nappa P, Ocampo-Garza SS, Annunziata MC, Cantelli M, Patruno C, et al. Comparative clinical, trichoscopic and safety outcomes of baricitinib, ritlecitinib and upadacitinib in alopecia areata: a real-world experience. Clin Exp Dermatol. 2026;51:491\u20133. https:\/\/doi.org\/10.1093\/ced\/llaf509.","journal-title":"Clin Exp Dermatol"},{"key":"1850_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243556","volume":"14","author":"T Passeron","year":"2023","unstructured":"Passeron T, King B, Seneschal J, Steinhoff M, Jabbari A, Ohyama M, et al. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Front Immunol. 2023;14:1243556. https:\/\/doi.org\/10.3389\/fimmu.2023.1243556.","journal-title":"Front Immunol"},{"key":"1850_CR30","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/jdv.20691","volume":"39","author":"D Saceda\u2010Corralo","year":"2025","unstructured":"Saceda\u2010Corralo D, Va\u00f1\u00f3\u2010Galv\u00e1n S. Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority. J Eur Acad Dermatol Venereol. 2025;39:1072\u20133. https:\/\/doi.org\/10.1111\/jdv.20691.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1850_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1576553","volume":"16","author":"Z Qi","year":"2025","unstructured":"Qi Z, Li Y. Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis. Front Pharmacol. 2025;16:1576553. https:\/\/doi.org\/10.3389\/fphar.2025.1576553.","journal-title":"Front Pharmacol"},{"key":"1850_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","volume":"188","author":"B King","year":"2023","unstructured":"King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi G-S, Blume-Peytavi U, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188:218\u201327. https:\/\/doi.org\/10.1093\/bjd\/ljac059.","journal-title":"Br J Dermatol"},{"key":"1850_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19090","author":"A Sechi","year":"2023","unstructured":"Sechi A, Song J, Dell\u2019Antonia M, Heidemeyer K, Piraccini BM, Starace M, et al. Adverse events in patients treated with Jak-inhibitors for alopecia areata: a systematic review. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19090.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1850_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","volume":"25","author":"B King","year":"2024","unstructured":"King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25:299\u2013314. https:\/\/doi.org\/10.1007\/s40257-024-00846-3.","journal-title":"Am J Clin Dermatol"},{"key":"1850_CR35","volume-title":"DailyMed: olumiant\u2014baricitinib tablet, film coated","author":"National Library of Medicine","year":"2026","unstructured":"National Library of Medicine. DailyMed: olumiant\u2014baricitinib tablet, film coated. Bethesda: National Library of Medicine; 2026."},{"key":"1850_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdin.2024.11.009","volume":"19","author":"G Xiong","year":"2025","unstructured":"Xiong G, Yu E, Heung M, Yang J, Lowe M, Abu-Hilal M. Weight gain secondary to the use of oral Janus kinase inhibitors: a systematic review and meta-analysis. JAAD Int. 2025;19:1\u20139. https:\/\/doi.org\/10.1016\/j.jdin.2024.11.009.","journal-title":"JAAD Int"},{"key":"1850_CR37","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/ced\/llaf144","volume":"50","author":"L Ibba","year":"2025","unstructured":"Ibba L, Gargiulo L, Bianco M, Di Giulio S, Cascio Ingurgio R, Alfano A, et al. Potential role of leptin in Janus kinase 2 inhibitor-associated weight gain: a monocentric retrospective study. Clin Exp Dermatol. 2025;50:1834\u20137. https:\/\/doi.org\/10.1093\/ced\/llaf144.","journal-title":"Clin Exp Dermatol"},{"key":"1850_CR38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003050","author":"N Moll\u00e9","year":"2020","unstructured":"Moll\u00e9 N, Krichevsky S, Kermani P, Silver RT, Ritchie E, Scandura JM. Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2\/STAT3. Blood. 2020. https:\/\/doi.org\/10.1182\/blood.2019003050.","journal-title":"Blood"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01850-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:38Z","timestamp":1788981698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01850-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1850"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01850-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional review board approval was exempted as the study protocol did not deviate from standard clinical practice. All patients received baricitinib or ritlecitinib according to good clinical practice and in accordance with Italian guidelines. All included patients had provided written informed consent for the retrospective use of data collected during routine clinical care (demographics and clinical scores). The study was conducted in accordance with the Helsinki Declaration of 1964 and its subsequent amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including privacy.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francesco D\u2019Oria, Sara Di Giulio, Costanza Falcidia, and Giulio Foggi have nothing to declare. Luciano Ibba has been a consultant and\/or speaker and has served as an advisory board member for Almirall and LEO Pharma. Carlo Alberto Vignoli has served as a consultant and as a speaker for Eli Lilly. Paola Facheris has served as a consultant for Eli Lilly and as a speaker for UCB, AbbVie, and Pfizer. Luigi Gargiulo has been a consultant and\/or speaker and has participated in advisory boards for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Incyte, Galderma, Pierre Fabre, Johnson and Johnson, Novartis, Pfizer, Sanofi, and UCB Pharma. Ruggero Cascio Ingurgio has served as a consultant for UCB Pharma. Alessandra Narcisi has served on advisory boards, received honoraria for lectures, and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Antonio Costanzo has served as an advisory board member, consultant, and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. Mario Valenti has been a consultant and\/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, Boehringer Ingelheim, Almirall, UCB and Difa Cooper. Mario Valenti is an Editorial Board Member of Dermatology and Therapy. Mario Valenti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}